Treatment strategies for myeloproliferative neoplasms

被引：0
作者：
Heidel, Florian [1 ]
机构：
[1] Univ Med Greifswald, Innere Med C Hamatol & Onkol Stammzelltransplanta, Sauerbruchstr, D-17475 Greifswald, Germany
来源：
ONKOLOGIE | 2022年 / 28卷 / 08期
关键词：
Myeloproliferative neoplasms; risk-adapted therapy; Polycythemia vera; Thrombocythemia; essential; Primary myelofibrosis; Janus kinase inhibitors; INTERNATIONAL PROGNOSTIC SCORE; POLYCYTHEMIA-VERA; MYELOFIBROSIS; RUXOLITINIB; THROMBOSIS; EFFICACY; THERAPY; SAFETY;
D O I：
10.1007/s00761-022-01191-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Classical chronic BCR::ABL1-negative myeloproliferative neoplasms include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). In recent years, there has been a significant improvement with respect to therapeutic options and strategies that include novel agents. Interferons, Janus kinase (JAK) inhibitors and combination treatment are among the clinical developments. An exact classification, diagnosis and risk stratification are crucial for optimizing the treatment strategy and personalized treatment.
引用
收藏
页码：721 / 730
页数：10
相关论文
共 29 条
  • [1] Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
    Alvarez-Larran, Alberto
    Pereira, Arturo
    Cervantes, Francisco
    Arellano-Rodrigo, Eduardo
    Hernandez-Boluda, Juan-Carlos
    Ferrer-Marin, Francisca
    Angona, Anna
    Gomez, Montse
    Muina, Begona
    Guillen, Helga
    Teruel, Anabel
    Bellosillo, Beatriz
    Burgaleta, Carmen
    Vicente, Vicente
    Besses, Carles
    [J]. BLOOD, 2012, 119 (06) : 1363 - 1369
  • [2] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
    Arber, Daniel A.
    Orazi, Attilio
    Hasserjian, Robert
    Thiele, Jurgen
    Borowitz, Michael J.
    Le Beau, Michelle M.
    Bloomfield, Clara D.
    Cazzola, Mario
    Vardiman, James W.
    [J]. BLOOD, 2016, 127 (20) : 2391 - 2405
  • [3] BARBUI T, 2021, LANCET, V8, pE17, DOI DOI 10.1016/S2352-3026(20)30373-2
  • [4] In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
    Barbui, Tiziano
    Carobbio, Alessandra
    Rumi, Elisa
    Finazzi, Guido
    Gisslinger, Heinz
    Rodeghiero, Francesco
    Randi, Maria Luigia
    Rambaldi, Alessandro
    Gisslinger, Bettina
    Pieri, Lisa
    Bertozzi, Irene
    Casetti, Ilaria
    Pardanani, Animesh
    Passamonti, Francesco
    Vannucchi, Alessandro M.
    Tefferi, Ayalew
    [J]. BLOOD, 2014, 124 (19) : 3021 - 3023
  • [5] Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
    Barbui, Tiziano
    Finazzi, Guido
    Carobbio, Alessandra
    Thiele, Juergen
    Passamonti, Francesco
    Rumi, Elisa
    Ruggeri, Marco
    Rodeghiero, Francesco
    Randi, Maria Luigia
    Bertozzi, Irene
    Gisslinger, Heinz
    Buxhofer-Ausch, Veronika
    De Stefano, Valerio
    Betti, Silvia
    Rambaldi, Alessandro
    Vannucchi, Alessandro M.
    Tefferi, Ayalew
    [J]. BLOOD, 2012, 120 (26) : 5128 - 5133
  • [6] Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
    Barbui, Tiziano
    Barosi, Giovanni
    Birgegard, Gunnar
    Cervantes, Francisco
    Finazzi, Guido
    Griesshammer, Martin
    Harrison, Claire
    Hasselbalch, Hans Carl
    Hehlmann, Rudiger
    Hoffman, Ronald
    Kiladjian, Jean-Jacques
    Kroeger, Nicolaus
    Mesa, Ruben
    McMullin, Mary F.
    Pardanani, Animesh
    Passamonti, Francesco
    Vannucchi, Alessandro M.
    Reiter, Andreas
    Silver, Richard T.
    Verstovsek, Srdan
    Tefferi, Ayalew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (06) : 761 - 770
  • [7] Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
    Crodel, Carl C.
    Jentsch-Ullrich, Kathleen
    Koschmieder, Steffen
    Kaempfe, Dietrich
    Griesshammer, Martin
    Doehner, Konstanze
    Jost, Philipp J.
    Wolleschak, Denise
    Isfort, Susanne
    Stegelmann, Frank
    Jilg, Stefanie
    Hofmann, Verena
    Auteri, Guiseppe
    Rachow, Tobias
    Ernst, Philipp
    Brioli, Annamaria
    von Lilienfeld-Toal, Marie
    Hochhaus, Andreas
    Palandri, Francesca
    Heidel, Florian H.
    [J]. LEUKEMIA, 2020, 34 (07) : 1949 - 1953
  • [8] Ginzburg Y, 2021, BLOOD, V138, P390
  • [9] Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
    Gisslinger, Heinz
    Klade, Christoph
    Georgiev, Pencho
    Krochmalczyk, Dorota
    Gercheva-Kyuchukova, Liana
    Egyed, Miklos
    Rossiev, Viktor
    Dulicek, Petr
    Illes, Arpad
    Pylypenko, Halyna
    Sivcheva, Lylia
    Mayer, Jiri
    Yablokova, Vera
    Krejcy, Kurt
    Grohmann-Izay, Barbara
    Hasselbalch, Hans C.
    Kralovics, Robert
    Kiladjian, Jean-Jacques
    [J]. LANCET HAEMATOLOGY, 2020, 7 (03): : E196 - E208
  • [10] Griesshammer M., 2021, PRIMARE MYELOFIBROSE
123